[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-hodgkins-lymphoma-nhl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-hodgkins-lymphoma-nhl":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":4,"leadSponsor":44,"locationsCount":47},"100139553","collection-of-human-samples-to-study-hairy-cell-and-other-leukemias-and-to-develop-recombinant-immunotoxins-for-cancer-treatment-100139553",false,"NCT01087333","Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment","A Study of Hairy Cell and Other Leukemias With a Focus on Recombinant Immunotoxins for Cancer Treatment","* INCLUSION CRITERIA:\n\nAll participants\n\n* 18 years of age and older\n* Desire of the individual to submit data and samples for research\n* Ability to understand and the willingness to sign a written informed consent document.\n\nIndividuals with cancer\n\n-Participants may have a diagnosis of hematologic malignancy or solid tumor. These participants would not be excluded if they were in long-term complete remission.\n\nNormal donors (Individuals without cancer)\n\n-Individuals must not have a current or prior diagnosis of a hematologic malignancy or solid tumor.\n\nEXCLUSION CRITERIA:\n\nAll participants\n\n-Known pregnancy at enrollment. NOTE: A pregnancy test will be required in individuals on study prior to any procedure done for research purposes that is greater than minimal risk.",true,"ALL","18 Years",{"count":20,"type":21},1263,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers. The investigators are particularly interested in samples from individuals who have diseases that can be treated with a new type of drug called immunotoxin, in which an antibody carrying a toxin binds to a cancer cell and allows the toxin to kill the cell.\n\nObjectives:\n\n\\- To collect a variety of clinical samples, including blood, urine, lymph samples, and other tissues, in order to study the samples and develop new treatments for leukemia.\n\nEligibility:\n\n\\- Individuals 18 years of age and older who have been diagnosed with leukemia or other kinds of blood and lymphatic system cancers, or who are healthy volunteers.\n\nDesign:\n\n* Individuals who have leukemia will be asked to provide blood, bone marrow, urine, and tumor tissue samples as requested by the researchers. Healthy volunteers will provide only blood and urine samples.\n* No treatment will be given as part of this protocol.",[25,26,27,28,29],"Hairy Cell Leukemia (HCL)","Chronic Lymphocytic Leukemia (CLL)","Non-Hodgkins Lymphoma (NHL)","Cutaneous T Cell Lymphoma (CTCL)","Adult T Cell Lymphoma (ATL)",[31,32,33,34,35,36],"Cytotoxicity Assay","Neutralizing Antibodies","Apheresis","Flow Cytometry","Hemolytic Uremic Syndrome (HUS)","Natural History","RECRUITING","2026-06-04",{"date":40,"type":41},"2026-06-05","ACTUAL",{"date":43,"type":41},"2010-03-02",{"name":45,"class":46},"National Cancer Institute (NCI)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100567249","phase-4-outcomes-of-early-and-late-administration-g-csf-for-primary-prophylaxis-in-non-hodgkins-lymphoma-patients-100567249","NCT06665737","Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients","A Comparison Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients Who Receive Chemotherapy, Multicenter Study","G-CSF in NHL","Inclusion Criteria:\n\n* Aged 18 years or old\n* Confirmed lymphoma undergoing standard chemotherapy\n* Signed an approval informed consent\n* Has a good understanding of Thai\n* Available for follow-up after chemotherapy\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Serious concomitant diseases and discontinuous treatment such as cardiovascular, liver, or kidney diseases\n* Contraindication to chemotherapy or G-CSF administration\n* Antibiotic use within 1 week prior to enrollment",{"count":57,"type":21},126,"INTERVENTIONAL",[60],"PHASE4","The goal of this clinical trial is to\n\nPrimary Objectives:\n\n1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during standard chemotherapy in a multicenter study\n2. To determine the incidence of leukopenia and neutropenia in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy in a multicenter study\n\nSecondary Objectives:\n\n1. To determine changes in white blood cell, hemoglobin, and platelet levels in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy.\n2. To determine the quality of life of patients with non-Hodgkin's lymphoma who undergoing standard chemotherapy and with neutropenia Researchers will compare the outcome between patients received either early G-CSF (within 72 hours) or late G-CSF (after 72 hours).\n\nAll patients will be followed up to monitor for febrile neutropenia events, other hematological parameters and quality of life.",[63,64,65,66],"Non-Hodgkin's Lymphoma (NHL)","Granulocyte Colony Stimulating Factor","Febrile Neutropenia (FN)","Myelosuppression Adult",[68,69,64,70],"Non-Hodgkin's lymphoma","Febrile neutropenia","Myelosuppression","NOT_YET_RECRUITING","2025-01-24",{"date":74,"type":41},"2025-01-28",{"date":76,"type":21},"2025-02-01",{"date":78,"type":21},"2026-12-31",{"name":80,"class":81},"Department of Medical Services Ministry of Public Health of Thailand","OTHER_GOV",3]